Heat shock protein 90 (HSP90), which regulates the functions of multiple oncogenic signaling pathways, has emerged as a novel anticancer therapeutic target, and multiple small molecule HSP90 inhibitors are now in clinical trials.
Introduction
HSP90 is a central participant in a multistep chaperoning process that folds and stabilizes a wide range of cellular clients. Tumor cells express high levels of HSP90 and have increased reliance on the HSP90 chaperoning pathway compared to normal cells (1) . This increased reliance on HSP90 has been attributed to several features of tumor cells. On the one hand, HSP90 plays critical roles in facilitating the survival and proliferation of tumors by chaperoning and supporting the activities of a multitude of key oncogenic proteins that promote tumorigenesis. These include wild-type and mutant receptor tyrosine kinases (e.g., EGFR family members, FLT-3, and BCR-ABL and NPM-ALK fusion proteins), signal-relaying serine-threonine kinases (AKT, Raf isoforms, Chk1, and CDK4), transcription factors (HIF-1α, steroid receptors, and mutant p53), telomerase, and proteins involved in apoptosis (Apaf-1, Bcl-2). In addition, HSP90 helps tumors survive the stressful environmental conditions associated with tumor proliferation. As a result, HSP90 has attracted considerable attention as a potential cancer therapy target; and multiple HSP90 inhibitors are now in clinical trials worldwide (2) .
Despite the intense interest in oncoprotein clients that are disabled by HSP90 inhibition and the potential of HSP90 inhibitors to treat malignancies, the effects of these inhibitors on tumor suppressor pathways have been largely unexplored.
Given that HSP90 inhibition of tumor suppressor pathways may negatively impact the effectiveness of HSP90 inhibitors, here we have examined the effects of HSP90 inhibition on the Hippo tumor suppressor pathway, which was first discovered to control organ size in Drosophila by regulating proliferation, cell growth, and apoptosis (3, 4) . Central regulators of this pathway in mammals are the LATS1 and LATS2 kinases (known as Warts in Drosophila), which are members of the nuclear Dbf-2-related (NDR) serine-threonine kinase family.
LATS1 and LATS2, which are activated by cell-cell contact, negatively regulate cell proliferation and organ size in mice (5, 6) . The activation states of LATS1 Sepharose, and bovine serum albumin from Sigma-Aldrich (St. Louis, MO); In vitro kinase assays. A549 were transiently transfected with plasmids that express SFB-LATS1 and the indicated tagged proteins. Forty-eight h after transfection, the cells were lysed and SFB-LATS1 was purified from the lysates by binding to streptavidin-agarose for 1-3 h with rotation at 4˚C. The beads were washed three times with lysis buffer followed by three washes with kinase buffer (50 mM HEPES, pH 7.4, 50 mM potassium acetate, 5 mM MgCl 2 , and 1 mM dithiothreitol). Kinase reactions were initiated by the addition of 1 µg GST-YAP (produced in E. coli by standard methods), 10 µCi [γ 32 P]-ATP, and 100 µM unlabeled ATP to the washed beads. The reactions were incubated for 15 min at 30˚C, stopped by the addition of SDS-PAGE sample buffer, heated to 95˚C for 10 min, separated by SDS-PAGE, and transferred to Immobilon P. Radioactivity on the membrane was detected and quantitated with a Storm Phosphorimaging system (GE Healthcare) prior to immunoblotting to detect tagged proteins. 17-AAG were due to HSP90 inhibition, we also showed that radicicol (Fig. 1C) , a structurally unrelated HSP90 inhibitor (42) , and PU-H71 (Fig. 1D) , a metabolically stable purine-scaffold HSP90 inhibitor (43) at the G1/S border with hydroxyurea (HU) for 24 h ( Fig. 2A) and then treating them with 17-AAG for increasing times while in the continued presence of HU.
As shown in Fig. 2A and B, 17-AAG did not relieve the cell arrest caused by HU;
yet both LATS1 and LATS2 were depleted by 17-AAG in the HU-arrested cells,
indicating that the effects of 17-AAG on LATS1 and LATS2 levels are not the result of cell cycle perturbations and suggesting that the LATS kinases might be HSP90 clients. In accord with that prediction, we found that LATS2 (Fig. 2C ) and LATS1 ( Fig. 2D) immunoprecipitates contained HSP90. Furthermore, the interaction between LATS1 and HSP90 was disrupted by 17-AAG (Fig. 2D) as has been observed with other HSP90 clients (34) . Taken together, these results demonstrate that these kinases are novel HSP90 clients.
HSP90 inhibition reduces LATS1 catalytic activity. We also assessed how LATS1 kinase activity was affected by HSP90 inhibition. We first attempted to assess the activity of endogenous LATS1 in subconfluent and confluent A549 cells; however, we were unable to detect LATS1 kinase activity with in vitro kinase assays using immunopurified LATS1 (data not shown). As an alternative approach, cells were transfected with SFB-tagged LATS1 alone or with the LATS activators MST2 and MOB1B. MST2 is a serine-threonine kinase that phosphorylates LATS1 on a C-terminal hydrophobic motif required for LATS1 activation, and MOB1 is a small protein that binds LATS1 and increases LATS1 kinase activity by inducing autophosphorylation of the LATS1 activation loop in the catalytic domain (45) . Following treatment of the cells with vehicle or 17-AAG, the SFB-tagged LATS1 was purified using streptavidin-agarose and the activity of the bead-bound LATS1 was assessed using GST-YAP as a substrate.
In the absence of co-expressed MOB1B and MST2, LATS1 kinase activity was not above background levels (Fig. 3A) , whereas the co-expression of MOB1B
and MST2 dramatically activated LATS1, consistent with previous findings.
Surprisingly, however, although 17-AAG caused reductions in LATS1 autokinase activity and YAP phosphorylation ( Fig. 3A and 3B ), LATS1 levels did not decrease with drug treatment. One possible explanation for this result is that stability in response to 17-AAG, MOB1B strongly stabilized LATS1 (Fig. 3C) .
Similarly, and consistent with our in vitro kinase results, co-expression of both and LATS2 (data not shown but see Fig. 1 ). Importantly, similar effects on LATS1
and YAP phosphorylation were also seen with the HSP90 inhibitor PU-H71 ( cancer. An analysis of these samples revealed several pertinent findings (Fig.   4D ). First, all tumors expressed LATS1, but the levels were highly variable, with some expressing very low levels (Pt. 1) and others expressing far higher levels 
